

Abstract EP262/#530 Table 2

Parameter		Hazard Ratio (95% CI, P value)		
		Overall Survival	Progression Free Survival	Time to Recurrence
Age at diagnosis	1 year	1.01 (0.98-1.05, 0.51)	1.02 (0.98-1.05, 0.36)	1.01 (0.98-1.04, 0.56)
Chemo	IV vs IP	1.45 (0.65-3.24, 0.37)	1.48 (0.76-2.89, 0.24)	1.47 (0.74-2.92, 0.27)
Stage	II vs I	2.11 (0.91-4.89, 0.08)		
BRCA status	+ vs -	0.75 (0.23-2.39, 0.11)	1.03 (0.42-2.55, 0.06)	0.87 (0.33-2.26, 0.05)
	Unk vs -	0.37 (0.14-0.93, 0.03)	0.36 (0.15-0.85, 0.02)	0.30 (0.11-0.81, 0.01)

Results 77 and 60 patients received IP/IV and IV chemotherapy, respectively. Those who received IP/IV were significantly younger. Stage distribution was similar between treatment groups. There were 24.7% and 5% confirmed BRCA mutation carriers, but 13% and 26.7% with unknown BRCA status in the IP/IV and IV groups, respectively. Five-year kaplan-meier outcomes were 77.7% vs. 67.7% TTR ($p=0.49$), 77.7% vs. 64.9% PFS ($p=0.44$), and 93.4% vs. 85.1% OS ($p=0.29$) in the IP/IV and IV groups, respectively. In multivariate analysis, IV chemotherapy trended towards shorter TTR, and worse PFS and OS. Those with unknown BRCA status had significantly better outcomes than confirmed BRCA negative (see tables 1 and 2).

Conclusion/Implications There are improved outcomes for patients with early stage HGSC who received IP/IV chemotherapy, although not statistically significant. The unknown BRCA status group could have unrecognized BRCA mutation carriers, possibly accounting for better outcomes than those without BRCA mutations.

Results Comparison of each category between frozen section and paraffin block revealed sensitivity of 83.5%, 100.0%, and 76.9% with specificity of 90.4%, 90.0%, and 95.5% for benign, borderline, and malignant diagnosis respectively. A 100% sensitivity for borderline diagnosis is the result of no false negative results in all 13 borderline cases. All results are found to be significant ($p<0.001$). Among 28 patients who were diagnosed with borderline cases by frozen section, the final pathological diagnosis was upgraded to malignant 14.3%, 46.4% remained borderline diagnosis and 39.3% diagnosed benign.

Conclusion/Implications Intraoperative frozen section is an important tool that can help manage the patient. But intraoperative frozen section must be calibrate to ensure the accuracy.

EP264/#775

GENOMIC ALTERATION BEFORE AND AFTER PROGRESSION ON FIRST EXPOSURE TO PARP INHIBITOR (PARPi) AMONG OVARIAN CANCER PATIENTS

¹Kyunglim Lee*, ²Yoo-Na Kim, ³Junsik Park, ³Yong Jae Lee, ⁴Jung-Yun Lee, ⁴Eunji Nam, ⁵Sang Wun Kim, ⁶Sunghoon Kim, ⁷Young Tae Kim. ¹Obstetrics and Gynecology, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of; ²Yonsei University College of Medicine/Severance hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of; ³Yonsei University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of; ⁴Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Women's Cancer Center, Yonsei Cancer Center, Institute of Women's Life Medical Science, Seoul, Korea, Republic of; ⁵Institute of Women's Life Medical Science, Yonsei University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of; ⁶Institute of Women's Life Medical Science, Yonsei University College of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of; ⁷Yonsei Cancer Center, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of

10.1136/ijgc-2023-IGCS.336

Introduction Nowadays, PARP inhibitor (PARPi) is frequently used as maintenance treatment in ovarian cancer patients. Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitors (PARPi) through the mechanism of synthetic lethality. When progressed after using the parp inhibitor, the genomic alteration of the tumor and the reuse of the parp inhibitor were not considered.

EP263/#236

ACCURACY OF INTRAOPERATIVE FROZEN SECTION DIAGNOSIS IN OVARIAN TUMORS

Bismarck Laihada*, Frank Wagey, Anton Suwito. Sam Ratulangi University, Obstetrics and Gynecology, Manado, Indonesia

10.1136/ijgc-2023-IGCS.335

Introduction Diagnosis of ovarian tumors are challenging and requires a pathologist expertise in its diagnosis process. Intraoperative frozen section serves as an important diagnostic tool for intraoperative settings. However, accuracy remains an important factor in frozen section diagnosis. This study is comparing frozen section diagnosis to paraffin block as the gold standard in Prof. Dr. R.D. Kandou Regional Hospital.

Methods This cross-sectional study is conducted in Prof. Dr. R.D. Kandou Regional Hospital during June 2021 to June 2022 obtained by medical records of all patients undergoing intraoperative frozen section and will be compared with paraffin block. Data are then analyzed in IBM Statistics SPSS 25.